Shots:

• The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland
• Vertex will collect real-world data on the combination therapies which will support future regulatory submission to the Scottish Medicines Consortium (SMC) following the 5yrs. access agreement
• Orkambi is a combination therapy used to treat people with CF who have two copies of the F508del mutation. Symkevi is a combination regimen for the treatment of patients with CF aged ≥12yrs. who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation with CFTR gene mutation

 Click here to­ read full press release/ article

 Ref: Vertex | Image: Vertex